{"id":57097,"date":"2026-02-13T18:56:05","date_gmt":"2026-02-13T10:56:05","guid":{"rendered":"https:\/\/flcube.com\/?p=57097"},"modified":"2026-02-13T18:56:06","modified_gmt":"2026-02-13T10:56:06","slug":"gsk-reports-7-revenue-growth-to-44-7-billion-in-2025-oncology-surges-43","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57097","title":{"rendered":"GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%"},"content":{"rendered":"\n

GlaxoSmithKline plc (GSK, NYSE:\u202fGSK<\/a>)<\/strong> delivered strong 2025 financial results<\/strong>, with total revenues rising 7% in constant currency to GBP\u202f32.67 billion (USD\u202f44.7 billion)<\/strong>, driven by double-digit growth in Respiratory\/Immunology, Oncology, and HIV<\/strong>. CEO Luke Miels<\/strong> highlighted broad-based performance<\/strong>, with specialty medicines up 17%<\/strong> and key franchises<\/strong>\u2014including Shingrix, Nucala, Benlysta, and Jemperli<\/strong>\u2014exceeding expectations. The UK-based pharma giant<\/strong> confirmed 2026 guidance of 3-5% turnover growth<\/strong>, supported by regulatory milestones<\/strong> for Exdensur, linerixibat, and bepirovirsen<\/strong>.<\/p>\n\n\n\n

Financial Performance Summary<\/h2>\n\n\n\n
Metric<\/th>2025 Result<\/th>YoY Change (CC)<\/th>Key Driver<\/th><\/tr><\/thead>
Total Revenue<\/strong><\/td>GBP\u202f32.67B (USD\u202f44.7B)<\/td>+7%<\/strong><\/td>Specialty medicines (+17%); Shingrix, Nucala, Benlysta strength<\/td><\/tr>
Q4 Revenue<\/strong><\/td>GBP\u202f8.6B (USD\u202f11.8B)<\/td>+8%<\/strong><\/td>Quarterly acceleration; oncology momentum<\/td><\/tr>
2026 Guidance<\/strong><\/td>3-5% turnover growth<\/td>\u2013<\/td>Exdensur launch; pipeline execution<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Segment Performance<\/h2>\n\n\n\n

Specialty Medicines: +17% to GBP\u202f13.5B<\/h3>\n\n\n\n
Franchise<\/th>2025 Sales<\/th>YoY Growth<\/th>Key Products<\/th><\/tr><\/thead>
HIV<\/strong><\/td>GBP\u202f7.7B<\/td>+11%<\/strong><\/td>Dovato, Triumeq, Juluca<\/td><\/tr>
Respiratory\/Immunology (RI&I)<\/strong><\/td>GBP\u202f3.8B<\/td>+18%<\/strong><\/td>Nucala, Benlysta, Exdensur (new)<\/td><\/tr>
Oncology<\/strong><\/td>GBP\u202f1.98B<\/td>+43%<\/strong><\/td>Jemperli, Ojjaara, Zejula<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Other Segments<\/h3>\n\n\n\n

| Vaccines<\/strong> | Flat (+2%) | Shingrix strength offset by Arexvy US decline |
| General Medicines<\/strong> | -1% | Legacy portfolio erosion |<\/p>\n\n\n\n

Key Product Performance<\/h2>\n\n\n\n
Product<\/th>2025 Sales<\/th>YoY Growth<\/th>Strategic Context<\/th><\/tr><\/thead>
Shingrix (shingles)<\/strong><\/td>GBP\u202f3.56B (USD\u202f4.84B)<\/td>+8%<\/strong><\/td>#1 revenue contributor<\/strong>; 42% Europe growth<\/strong>, 17% US<\/strong>, China recovery<\/strong><\/td><\/tr>
Nucala (asthma)<\/strong><\/td>GBP\u202f2.0B (USD\u202f2.7B)<\/td>+15%<\/strong><\/td>IL-5 leader<\/strong>; severe eosinophilic asthma expansion<\/td><\/tr>
Benlysta (lupus)<\/strong><\/td>GBP\u202f1.8B (USD\u202f2.4B)<\/td>+22%<\/strong><\/td>First approved lupus biologic<\/strong>; SLE and LN growth<\/strong><\/td><\/tr>
Jemperli (endometrial cancer)<\/strong><\/td>GBP\u202f861M (USD\u202f1.2B)<\/td>+89%<\/strong><\/td>dMMR\/MSI-H tumor-agnostic approval<\/strong>; combination with chemotherapy<\/strong><\/td><\/tr>
Ojjaara (myelofibrosis)<\/strong><\/td>GBP\u202f554M (USD\u202f784M)<\/td>+60%<\/strong><\/td>JAK inhibitor + ACVR1 mechanism<\/strong>; anemia benefit differentiation<\/strong><\/td><\/tr>
Arexvy (RSV)<\/strong><\/td>GBP\u202f593M (USD\u202f807M)<\/td>+2%<\/strong><\/td>US demand decline<\/strong>; seasonal variability<\/strong>; infant\/maternal programs pending<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

2026 Pipeline Milestones<\/h2>\n\n\n\n
Asset<\/th>Indication<\/th>Status<\/th>Strategic Value<\/th><\/tr><\/thead>
Exdensur (depemokimab)<\/strong><\/td>Severe asthma (eosinophilic); CRSwNP<\/td>UK approved Dec\u202f2025<\/strong>; US\/Japan approved; EU\/China 2026<\/strong><\/td>First twice-yearly biologic<\/strong>; compliance advantage<\/strong>; Nucala successor potential<\/strong><\/td><\/tr>
Linerixibat<\/strong><\/td>Cholestatic pruritus in PBC<\/td>US FDA decision pending<\/strong> (NDA filed June\u202f2025)<\/td>First IBAT inhibitor<\/strong> for PBC; orphan disease premium<\/strong><\/td><\/tr>
Bepirovirsen<\/strong><\/td>Hepatitis B “functional cure”<\/td>Full data readouts; NDA filings 2026<\/strong><\/td>Potential game-changer<\/strong>; sustained HBsAg\/DNA clearance<\/strong>; $10B+ market opportunity<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding GSK’s 2026 revenue growth, Exdensur commercial launch trajectory, and bepirovirsen regulatory approval timelines. Actual results may differ due to competitive dynamics in asthma (dupilumab, tezepelumab), RSV vaccine market saturation, and hepatitis B functional cure validation.-Fineline Info & Tech<\/a><\/p>\n\n\n\n